Atlas Trials

Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

Clinical trial NCT01727232 · COMPLETED

Trial details

NCT number
NCT01727232
Sponsor
Henri Mondor University Hospital
Status
COMPLETED
Study type
OBSERVATIONAL
Primary Immune Thrombocytopenia
Start date
2007-01-01
Primary completion
2012-06-01
Enrollment
107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.